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Table 1. Demographics

Piperacillin-tazobactam is a broad spectrum, commonly prescribed
antibiotic
It has adequate distribution in most parts of the body and tends to
be the agent of choice when Pseudomonas sp. along with
anaerobic coverage is warranted
Due to the widespread use of this agent, circumstances of
overuse, misuse, and resistance are of rising concern

Focus needs to be placed on appropriate initiation and deescalation of piperacillin-tazobactam as more information becomes
available

Characteristics

Analysis Group

Mean age

62 years

Female (%)

37 (42%)

Admitted to ICU

24 (27.3%)

Average CrCl

73 mL/min

Table 2. Pseudomonal Risk Factors

Emphasis should be on assessing patient-specific risk factors for
Pseudomonas sp.

Objective
The purpose of this medication use evaluation is to assess
appropriate use of piperacillin-tazobactam based on patient-specific
risk factors, actions taken to de-escalate when warranted, and identify
areas for improvement.

Pseudomonal Risk Factors

Number of Patients (%)

Recent hospitalization for at least 2
days within 90 days

53 (60.2%)

IV antibiotics within 90 days

48 (54.5%)

Immunocompromised
History of Pseudomonas within 6
month
Note: risk factors are not mutually exclusive

Methods

4 (4.5%)
2 (2.3%)

Figure 1. Initial Indications

Retrospective medication utilization evaluation
Study Period:

Inclusion Criteria:

Method:

August 1st to
September 15th
2021

At least 18 years of
age, received at
least one dose of
piperacillintazobactam

Patients were
randomly selected
from a clinical
support software
generated list

• Day 1: demographic data, risk factors, and empiric indication was
collected
• Demographic data include age, gender, creatinine clearance,
location in the hospital, and whether they were ever in the
intensive care unit (ICU)
• Risk factor data include previous hospitalization within 90 days,
previous IV antibiotic use within 90 days, history of pseudomonas
within 6 months, immunosuppressive state, and co-morbidities
associated with certain disease states (e.g. COPD for
pneumonia)
• Day 3: definitive indication, relevant positive cultures, and
appropriateness of action taken were documented
• If any patient deceased during the 3 day assessment period, it
was noted as well
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Figure 3. Action Taken - Day 3

Figure 2. Empiric Use - Day 1
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Inappropriate

Conclusion
The majority of piperacillin-tazobactam orders were initiated
appropriately and interventions were routinely made by pharmacists on
day 3 of therapy; however, more surveillance and a structured deescalation protocol would further aid in this process. Antimicrobial
stewardship and the importance of the pharmacists’ role in its
implementation continues to be an integral part of patient care and
antimicrobial resistance containment measure. It is important to use
broad spectrum antibiotics appropriately and de-escalate when clinically
indicated. Areas of focus for improvement include proper usage and
continual monitoring for intervention opportunities.
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• The most common indication for initiating piperacillin-tazobactam was
sepsis (21.6%), followed by skin and soft tissue infections (18.2%),
abdominal peritoneal infections (17.0%), hospital/ventilator-acquired
pneumonia (11.4%), empiric (6.8%), and complicated urinary tract
infections (5.7%)
• Inappropriately piperacillin-tazobactam initiations, according to the
pre-defined criteria, largely consisted of abdominal peritoneal
infections
• Inability to de-escalate was closely associated with the lack of
cultures
• On day 1, 80.7% of piperacillin-tazobactam initiations were
appropriate based on pre-defined patient-specific risk factors and
clinical judgement
• Raveh et al. found that the appropriateness rate of piperacillintazobactam use in their study hospital was 90%1 whereas Antoine et
al. determined the appropriateness was 71% in the four hospitals
they examined2
• This value highly varies between different institutions and largely
depend on the patient and health care professional population
• On day 3, 42% of orders were de-escalated or discontinued, 56% of
orders were continued, and 2.3% of orders were escalated. 80.7% of
actions taken were deemed appropriate
• Within the patients examined for this evaluation, only 37.5% had
positive cultures where 4.5% lead to de-escalation or discontinuation
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